Received Jul 2, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPA | HEP A (HAVRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 4T93R | — |
administration of an adult dose on a eighteen year old patient; administration of an adult dose on a eighteen year old patient; This non-serious case was reported by a nurse via call center representative and described the occurrence of adult use of a child product in a 18-year-old female patient who received HAV (Havrix adult) (batch number 4T93R, expiry date 11-JUL-2026) for prophylaxis. On 20-JUN-2025, the patient received Havrix adult. On 20-JUN-2025, an unknown time after receiving Havrix adult, the patient experienced adult use of a child product (Verbatim: administration of an adult dose on a eighteen year old patient) and overdose (Verbatim: administration of an adult dose on a eighteen year old patient). The outcome of the adult use of a child product and overdose were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 24-JUN-2025 The Vaccine Administration Facility was the same as Primary Reporter Registered Nurse called asking for safety advise on the administration of an adult dose on a eighteen year old patient which led to adult use of a child product and overdose. No further information was obtained in this call.